Home Metabolism Acetyl-CoA carboxylase

Acetyl-CoA carboxylase

Isoform-selective Products

Acetyl-CoA carboxylase Products

  • All (9)
  • Acetyl-CoA carboxylase Inhibitors (7)
  • New Acetyl-CoA carboxylase Products
Catalog No. Product Name Information Product Use Citations Product Validations
S8893 Firsocostat (GS-0976, ND-630) Firsocostat (GS-0976, ND-630) is a reversible inhibitor of acetyl CoA carboxylase (ACC) with IC50s of 2.1 nM,6.1 nM for hACC1 and hACC2,respectively.
Adv Sci (Weinh), 2024, 11(46):e2401311
Nat Commun, 2023, 14(1):1362
Genome Med, 2022, 14(1):67
S6753 CP 640186 CP 640186 is an isozyme-nonselective ACC (Acetyl-CoA carboxylase) inhibitor with IC50 values of 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively.
Exp Ther Med, 2020, 20(1):521-529
Molecules, 2015, 20(9):16221-34
Molecules, 2015, 20(9):16221-34
S8377 ND646 ND-646 is an allosteric inhibitor of the ACC (Acetyl-coA carboxylase) enzymes that prevents ACC subunit dimerization to suppress fatty acid synthesis with IC50 of 3.5 nM and 4.1 nM for hACC1 and hACC2, respectively.
Cancer Discov, 2023, 13(2):496-515
Cancer Sci, 2023, 114(4):1651-1662
Cancer Sci, 2023, 114(4):1651-1662
S6690 TOFA TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, TOFA is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. TOFA blocks fatty acid synthesis and induces cell death in a dose-dependent manner.
Cell Death Dis, 2024, 15(10):755
bioRxiv, 2024, 2024.02.22.581432
Cancer Commun (Lond), 2022, 10.1002/cac2.12380
S6672 PF-05175157 PF-05175157 is a broad-spectrum effective ACC inhibitor with IC50 of 27.0 nM, 33.0 nM, 23.5 nM and 50.4 nM for human ACC1, human ACC2, rat ACC1, and rat ACC2, respectively.
Nat Commun, 2025, 16(1):509
Cancer Cell Int, 2023, 23(1):83
Liver Res-Prc, 2023, Volume 7, Issue 2 Pages 124-135
F0270New Acetyl-CoA Carboxylase Rabbit mAb Acetyl-CoA carboxylase 1, Acetyl-Coenzyme A carboxylase alpha, ACC1, ACC-alpha, ACC α, ACACA, ACAC, ACCA, ACC-beta, ACC β, ACACB, ACC2, ACCB, Acetyl-CoA carboxylase 2
S5519 4-Methylsalicylic acid 4-Methylsalicylic acid (m-Cresotic acid, 2-Hydroxy-4-methylbenzoic acid, m-Cresotinic acid, 2-Hydroxy-p-toluic acid) is used to inhibit the medium chain acyl-CoA synthetase.
S6145 PF-05221304 PF-05221304 is an orally bioavailable, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL).
S6112 Oxalacetic acid Oxalacetic acid (Oxaloacetic acid, 2-Oxosuccinic acid, Ketosuccinic acid) is an intermediate of the citric acid cycle, where it reacts with acetyl-CoA to form citrate, catalysed by citrate synthase. It is also involved in gluconeogenesis, urea cycle, glyoxylate cycle, amino acid synthesis, and fatty acid synthesis. Oxaloacetate is also a potent inhibitor of Complex II.
S8893 Firsocostat (GS-0976, ND-630) Firsocostat (GS-0976, ND-630) is a reversible inhibitor of acetyl CoA carboxylase (ACC) with IC50s of 2.1 nM,6.1 nM for hACC1 and hACC2,respectively.
Adv Sci (Weinh), 2024, 11(46):e2401311
Nat Commun, 2023, 14(1):1362
Genome Med, 2022, 14(1):67
S6753 CP 640186 CP 640186 is an isozyme-nonselective ACC (Acetyl-CoA carboxylase) inhibitor with IC50 values of 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively.
Exp Ther Med, 2020, 20(1):521-529
Molecules, 2015, 20(9):16221-34
Molecules, 2015, 20(9):16221-34
S8377 ND646 ND-646 is an allosteric inhibitor of the ACC (Acetyl-coA carboxylase) enzymes that prevents ACC subunit dimerization to suppress fatty acid synthesis with IC50 of 3.5 nM and 4.1 nM for hACC1 and hACC2, respectively.
Cancer Discov, 2023, 13(2):496-515
Cancer Sci, 2023, 114(4):1651-1662
Cancer Sci, 2023, 114(4):1651-1662
S6690 TOFA TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, TOFA is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. TOFA blocks fatty acid synthesis and induces cell death in a dose-dependent manner.
Cell Death Dis, 2024, 15(10):755
bioRxiv, 2024, 2024.02.22.581432
Cancer Commun (Lond), 2022, 10.1002/cac2.12380
S6672 PF-05175157 PF-05175157 is a broad-spectrum effective ACC inhibitor with IC50 of 27.0 nM, 33.0 nM, 23.5 nM and 50.4 nM for human ACC1, human ACC2, rat ACC1, and rat ACC2, respectively.
Nat Commun, 2025, 16(1):509
Cancer Cell Int, 2023, 23(1):83
Liver Res-Prc, 2023, Volume 7, Issue 2 Pages 124-135
S5519 4-Methylsalicylic acid 4-Methylsalicylic acid (m-Cresotic acid, 2-Hydroxy-4-methylbenzoic acid, m-Cresotinic acid, 2-Hydroxy-p-toluic acid) is used to inhibit the medium chain acyl-CoA synthetase.
S6145 PF-05221304 PF-05221304 is an orally bioavailable, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL).
F0270New Acetyl-CoA Carboxylase Rabbit mAb Acetyl-CoA carboxylase 1, Acetyl-Coenzyme A carboxylase alpha, ACC1, ACC-alpha, ACC α, ACACA, ACAC, ACCA, ACC-beta, ACC β, ACACB, ACC2, ACCB, Acetyl-CoA carboxylase 2

Choose Selective Acetyl-CoA carboxylase Inhibitors

Tags: Acetyl-CoA carboxylase inhibitor|Acetyl-CoA carboxylase agonist|Acetyl-CoA carboxylase activator|Acetyl-CoA carboxylase inducer|Acetyl-CoA carboxylase antagonist|Acetyl-CoA carboxylase signaling pathway|Acetyl-CoA carboxylase assay kit